| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/23/2006 | US20060063143 Immortalized hypothalamic neuronal cell lines |
| 03/23/2006 | US20060062859 Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes |
| 03/23/2006 | US20060062842 Method of administering a compound to multi-drug resistant cells |
| 03/23/2006 | US20060062805 Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
| 03/23/2006 | US20060062801 Immunogens; electrical injection; electroporation |
| 03/23/2006 | US20060062799 Sperm specific lysozyme-like proteins |
| 03/23/2006 | US20060062795 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
| 03/23/2006 | US20060062791 I kappa B kinase complex as a target for the treatment of Huntington's disease |
| 03/23/2006 | US20060062790 AKT3 inhibitors |
| 03/23/2006 | US20060062785 Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia |
| 03/23/2006 | US20060062780 Myelin oligodendrocyte glycoprotein; 1st domain: deimmunized, autoreactive antigen specifically recognized by Ig receptors of autoreactive B-cells; 2nd domain: effector molecule capable of interacting with or activating NK-cells, T-cells, macrophages, monocytes or granulocytes; autoimmune diseases |
| 03/23/2006 | US20060062777 Inhibit tumor growth, or metastasis by modifying protein-protein interactions involving certain amino acid sequences within matrix metalloproteinase 9 (MMP-9) |
| 03/23/2006 | US20060062776 Modified anticholinergic neurotoxins as modulators of the autoimmune reaction |
| 03/23/2006 | US20060062775 Method for the production of protamine |
| 03/23/2006 | US20060062772 Polypeptide delivery system |
| 03/23/2006 | US20060062769 Using nestin-positive pancreatic stem cell to generate insulin producing beta cells; tissue engineering and repair; regenerative medicine |
| 03/23/2006 | US20060062765 Lentiviral vector-mediated gene transfer and uses thereof |
| 03/23/2006 | US20060062762 Method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of interstitial cystitis treatment; method of acquired immune deficiency syndrome treatment; and method of herpes treatment |
| 03/23/2006 | US20060062761 Modified interferon alpha with reduced immunogenicity |
| 03/23/2006 | US20060062760 Use of interleukin-11 to prevent immune-mediated cytotoxicity |
| 03/23/2006 | US20060062759 Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
| 03/23/2006 | US20060062758 Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds |
| 03/23/2006 | US20060062757 mixing imiquimod and a base cream, then topically administering the resulting mixture, in conjunction with vaccines containing tumor necrosis factors, and valacyclovir tablets admistered by mouth, and testing for tumor markers; mammary glands |
| 03/23/2006 | US20060062756 Method of cancer screening; method of cancer treatment; method of diabetes treatment; method of multiple sclerosis treatment; method of interstitial cystitis treatment; method of acquired immune deficiency syndrome treatment; and method of herpes treatment |
| 03/23/2006 | US20060062755 medical diagnosis using tumor markers; concurrent transdermal administration of imiquimod and injection of vaccines containing tumor necrosis factors; anticarcinogenic agents |
| 03/23/2006 | US20060062754 Polymeric modifiers and pharmaceutical compositions |
| 03/23/2006 | US20060062727 Compositions and methods for the diagnosis and treatment of tumor |
| 03/23/2006 | DE4007605B4 SDK-Peptide, Verfahren zu ihrer Herstellung und diese enthaltende therapeutischen Zusammensetzungen SDK peptides, process for their preparation and therapeutic compositions containing |
| 03/23/2006 | DE10344561A1 Use of proteins and peptides from royal jelly, as antibacterial, fungicidal and antiviral agents, where activity is associated with short amino acid sequences |
| 03/23/2006 | DE102004043153A1 Erfindung betreffend GLP-1 und Exendin Invention concerning GLP-1 and exendin |
| 03/23/2006 | DE102004037805B3 Verfahren zur Hitzebehandlung fibrinogenhaltiger pharmazeutischer Zubereitungen Heat treatment process for fibrinogen pharmaceutical preparations |
| 03/23/2006 | DE102004036780A1 In-vitro preparation of material mixture, for diagnosing and/or curing tumor, comprises absorbing autologous tumor-specific heat shock proteins at monocyte, locating electrically and/or magnetically and combining heatable nanoparticles |
| 03/23/2006 | CA2823429A1 Sialidase catalytic domain proteins |
| 03/23/2006 | CA2584553A1 External agent for treatment of skin ulcer |
| 03/23/2006 | CA2583199A1 The use of an inhibitor of heterotetrameric annexin 2 for treating viral infections |
| 03/23/2006 | CA2580564A1 Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds |
| 03/23/2006 | CA2580517A1 Protein a compositions and methods of use |
| 03/23/2006 | CA2580372A1 Isolation of growth and differentiating factors from colostrum |
| 03/23/2006 | CA2580236A1 Purinenucleoside derivative modified in 8-position and medical use thereof |
| 03/23/2006 | CA2580107A1 Growth factor treatment for asthma |
| 03/23/2006 | CA2580010A1 Use of gilz protein expressed in dendritic cells to modulate an antigen-specific immune response |
| 03/23/2006 | CA2580004A1 Compositions and methods of using alpha-fetoprotein growth inhibitory peptides |
| 03/23/2006 | CA2578940A1 Ica512 couples insulin secretion and gene expression in .beta.-cells |
| 03/23/2006 | CA2577336A1 Permucosal composition and method of improving permucosal absorption |
| 03/23/2006 | CA2576940A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 03/23/2006 | CA2576768A1 Method of reducing the effects of a.beta. and compositions therefore |
| 03/23/2006 | CA2574719A1 Inhibition of feline calicivirus replication by asparaginase |
| 03/22/2006 | EP1637608A2 Recombinant adenoviral vector and methods of use |
| 03/22/2006 | EP1637600A1 Chromosome 1 gene and gene products related to Alzheimer's disease |
| 03/22/2006 | EP1637598A1 Cd47 partal peptdie and anti-shps-1 monoclonal antibody |
| 03/22/2006 | EP1637592A1 Neuronal progenitor cells, methods to produce them and uses thereof for the therapy of neural defects |
| 03/22/2006 | EP1637540A1 Hyperactive Stat molecules and their use in assays employing gene activation |
| 03/22/2006 | EP1637173A2 Particle delivery |
| 03/22/2006 | EP1637162A1 MEDICINAL COMPOSITION FOR PREVENTING OR TREATING Th1 TYPE IMMUNOLOGICAL DISEASE |
| 03/22/2006 | EP1637161A1 REMEDY FOR CEREBRAL NEURODEGENERATIVE DISEASES USING PPAR&dgr; AGONIST |
| 03/22/2006 | EP1637157A1 Pharmaceutical composition for the treatment of pelvic pain |
| 03/22/2006 | EP1637156A1 Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases |
| 03/22/2006 | EP1637155A1 Method of mudulating memory effector T-cells using a CD2-binding agent, and compositions |
| 03/22/2006 | EP1637154A2 High molecular weight medicine-containing preparation in powder form for administration through mucosa |
| 03/22/2006 | EP1637142A2 Stable solid formulation of enalapril salt and process for preparation thereof |
| 03/22/2006 | EP1636561A2 Combinatorial protein library screening by periplasmic expression |
| 03/22/2006 | EP1636376A2 Differential gene expression in schizophrenia |
| 03/22/2006 | EP1636365A1 Cholesterol biosynthesis pathway modulators and uses thereof |
| 03/22/2006 | EP1636364A2 INHIBITION OF APOPTOSIS-SPECIFIC ELF-5A ( EIF-5A1) WITH ANTISENSE OLIGONUCLEOTIDES AND siRNAs AS ANTI-INFLAMMATORY THERAPEUTICS |
| 03/22/2006 | EP1636363A1 Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer |
| 03/22/2006 | EP1636359A2 Methods for treating pain |
| 03/22/2006 | EP1636358A2 Mutants of the factor vii epidermal growth factor domain |
| 03/22/2006 | EP1636340A2 Unnatural reactive amino acid genetic code additions |
| 03/22/2006 | EP1636335A2 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase |
| 03/22/2006 | EP1636269A2 Extracellular aspergillus polypeptides |
| 03/22/2006 | EP1636267A2 Modified hirudin proteins and t-cell epitopes in hirudin |
| 03/22/2006 | EP1636266A2 Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof |
| 03/22/2006 | EP1636263A2 Pegylated soluble gp130-dimers useful as a medicament |
| 03/22/2006 | EP1636261A2 Thrombopoietin proteins with improved properties |
| 03/22/2006 | EP1636259A2 Chemokine-binding protein thap1, methods and use thereof |
| 03/22/2006 | EP1636258A2 Angiogenic factor and inhibitors thereof |
| 03/22/2006 | EP1636257A2 Peptides enhancing ceh activity or acat inhibitory activity, pharmaceutical compositions comrising these peptides and their use in the treatment of atherosclerosis |
| 03/22/2006 | EP1636253A1 Biologically active peptide comprising tyrosyl-seryl-valine (ysv) |
| 03/22/2006 | EP1636252A1 Statine derivatives for the treatment of alzheimer s disease |
| 03/22/2006 | EP1636251A2 Ccn1 compositions and methods |
| 03/22/2006 | EP1636250A2 Self-assembling peptides incorporating modifications and methods of use thereof |
| 03/22/2006 | EP1636248A2 Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof |
| 03/22/2006 | EP1636232A2 Immunosuppressive effects of pteridine derivatives |
| 03/22/2006 | EP1636208A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 03/22/2006 | EP1635891A2 Pharmaceutical composition to prevent and treat epithelial wounds, immunomodulating pharmaceutical composition, pharmaceutical composition, insecticide, insecticide composition, insecticide use of lectin km+ to treat cicatrizations, use of lectin km+ to prepare immunomodulating medicament |
| 03/22/2006 | EP1635871A2 Methods and compositions for treating rheumatoid arthritis |
| 03/22/2006 | EP1635866A2 Modified antiviral peptides with increased activity and cell membrane affinity |
| 03/22/2006 | EP1635861A1 Compositions comprising factor viii and factor ixa for treating haemophilia |
| 03/22/2006 | EP1635860A2 Use of vegf-c or vegf-d in reconstructive surgery |
| 03/22/2006 | EP1635859A2 Use of pam |
| 03/22/2006 | EP1635858A2 Targeted delivery to legumain-expressing cells |
| 03/22/2006 | EP1635857A1 TREATMENT OF HAEMORRHAGIC SHOCK USING COMPLEMENT 5a RECEPTOR INHIBITORS |
| 03/22/2006 | EP1635856A2 Saposin c-dops: a novel anti-tumor agent |
| 03/22/2006 | EP1635855A2 Selective r-cadherin antagonists and methods |
| 03/22/2006 | EP1635854A2 Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| 03/22/2006 | EP1635848A1 Methods of managing the symptoms of premenstrual syndrome |
| 03/22/2006 | EP1635822A2 Methods and compositions for treating rheumatoid arthritis |
| 03/22/2006 | EP1635816A1 Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases |
| 03/22/2006 | EP1635805A2 Sigma ligands for neuronal regeneration and functional recovery |
| 03/22/2006 | EP1635796A1 Fast dissolving orally consumable films containing sucralose as a sweetener |